
An international team of researchers has demonstrated that the tetravalent dengue vaccine Qdenga provides significant protection against the disease under real-world conditions during the major 2024 epidemic in São Paulo, Brazil. The study, published in the journal The Lancet Infectious Diseases and led by Dr. Otavio Ranzani, head of the DataHealth Lab group at the Sant Pau Research Institute (IR Sant Pau). Together with Dr. Julio Croda, Fiocruz, Brazil, provides the first evidence of the vaccine’s effectiveness following its approval.